Pheon Therapeutics Appoints Industry Veteran Cyrus Mozayeni, Md As Chief Executive Officer
07/25/23, 7:27 AM
Location
londonIndustry
health care
therapeutics
biotechnology
Pheon Therapeutics , a leading Antibody-Drug Conjugate company developing next generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of Cyrus Mozayeni, MD as Chief Executive Officer. The appointment follows the decision of Bertrand Damour to step down as CEO and coincides with the recent appointment of Jeff Albers as Chairman of the Board.
Company Info
Location
london, england, united kingdom
Additional Info
Pheon Therapeutics is an Antibody Drug Conjugate (ADC) specialist developing a pipeline of monotherapies for novel targets and/or with novel payloads. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. Pheon's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.
Pheon is backed by expert, specialist healthcare investors Atlas Venture, Brandon Capital, Forbion and Research Corporation Technologies (RCT). Pheon has a world class, proven leadership team that brings together the best of ADC engineering, clinical and managerial expertise and track record. For further information, please visit www.pheontx.com